Trial Profile
Phase II randomized trial of DNX-2401 oncolytic adenovirus added to standard of care for newly diagnosed glioblastoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Jun 2020
Price :
$35
*
At a glance
- Drugs Tasadenoturev (Primary) ; Tasadenoturev (Primary)
- Indications Glioblastoma; Glioma
- Focus Adverse reactions
- 01 Jun 2020 Status changed from recruiting to discontinued.
- 12 Feb 2016 New trial record